The Bowers and colleagues canonical work across the 1980s and 1990s reported that co-administration of a GHRH-R agonist with a GHRP-class agent produced greater growth hormone release than either compound alone in healthy human volunteers, with the synergy mechanism interpreted as pulse-amplitude (GHRH-R) versus basal-frequency (GHS-R1a) control of pituitary somatotroph release plus differential engagement of the somatostatin tone [5]
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
No anti-AOD9604 antibodies were detected in the subset of patients selected for antibody assay
In the research community, sustained or supraphysiologic IGF-1 exposure is associated with progressive abdominal distension (sometimes called 'GH gut') and concern for cardiac hypertrophy
It targets GHRHR and GHSR1a receptors respectively, supporting comparative studies of GHaxis signaling, receptor interaction, and secretagogue synergy
Research Use Only This dual-secretagogue blend is supplied solely for qualified laboratory research and is not intended for human or veterinary administration
